An overview of the current state of phage therapy for the treatment of biofilm-related infections.
Journal
Current opinion in virology
ISSN: 1879-6265
Titre abrégé: Curr Opin Virol
Pays: Netherlands
ID NLM: 101560941
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
16
11
2021
revised:
27
12
2021
accepted:
22
01
2022
pubmed:
4
3
2022
medline:
12
5
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Bacterial biofilms are involved in many chronic and difficult-to-treat infections. Phage therapy against infectious biofilms is becoming a promising strategy, as suggested by the increasing number of publications demonstrating the efficacy of phages against in vitro formed biofilms. However, the translation between in vitro results to in vivo phage therapy outcome is not straightforward due to the complexity of phage-biofilm interactions in clinical contexts. Here, we provide a critical overview of the in vitro studies of phages for biofilm control of clinical pathogens, followed by the major outcomes and lessons learned from the recently reported case studies (between 2018 and 2021) of phage therapy against biofilm-related infections.
Identifiants
pubmed: 35240424
pii: S1879-6257(22)00016-5
doi: 10.1016/j.coviro.2022.101209
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101209Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.